Table 3

Comparison of relative affinity with in vitro and in vivo activities of anti-AT MAbsa

MAbKD (nM)Mean IC50 for RBC hemolysis (mg/ml)Mean EC50 for dermonecrosis (mg/kg)
2A3.10.600.300.107
10A7.50.500.300.088
12B8.190.480.440.082
28F6.113.14.150.906
  • a The differences in KD, mean IC50, and mean EC50 between 28F6.1 and the other three MAbs were 22- to 27-fold, 9- to 14-fold, and 9- to 11-fold, respectively.